Study of the Interest of the Combination of Stiripentol (Diacomit®) and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
Study of the Interest of the Combination of Stiripentol (Diacomit®) and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (Diacomit®) and Carbamazepine.
Inclusion Criteria:
The medical records of CRéER patients with the following criteria will be included in the retrospective part of the research by an investigator:
With pharmacoresistant epilepsy, i.e. a history of failure of two well-conducted and well-tolerated antiepileptic treatment regimens, either as monotherapy or as combination therapy,
Receiving or having received a treatment combining stiripentol and carbamazepine for a period of at least 15 days,
Having at least one evaluation data after the initiation of treatment with stiripentol and carbamazepine (a follow-up visit after the initiation of the study treatment),
For which an information note indicating the possibility of opposing the processing of data has been provided.
Among the patients whose medical records are included in the retrospective part of the research, those who meet the following criteria will be able to participate in the prospective part of the research:
Exclusion Criteria:
- Retrospective part of the research : Patients objecting to the collection of their data will not participate in the research.
- Prospective part of the research :
Patients with the following criteria will not be able to participate in the prospective part of the research: